Undiscovered Gems Highlight 3 Top Small Cap Stocks with Strong Metrics

In the current economic landscape, cooling inflation in the U.S. and strong bank earnings have propelled major stock indexes higher, while small-cap stocks, as evidenced by the S&P MidCap 400's notable gains, are also capturing attention amidst this positive momentum. With these dynamics in play, identifying small-cap stocks with robust financial metrics can be a strategic move for investors looking to capitalize on potential growth opportunities within this segment of the market.

Top 10 Undiscovered Gems With Strong Fundamentals

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Omega Flex	NA	0.39%	2.57%	★★★★★★
Wilson Bank Holding	NA	7.87%	8.22%	★★★★★★
SALUS Ljubljana d. d	13.55%	13.11%	9.95%	★★★★★★
Ovostar Union	0.01%	10.19%	49.85%	★★★★★★
MAPFRE Middlesea	NA	14.56%	1.77%	★★★★★☆
ASA Gold and Precious Metals	NA	7.11%	-35.88%	★★★★★☆
Sparta	NA	-5.54%	-15.40%	★★★★★☆
Pure Cycle	5.15%	-2.61%	-6.23%	★★★★★☆
Arab Banking Corporation (B.S.C.)	213.15%	18.58%	29.63%	★★★★☆☆
BOSQAR d.d	94.35%	39.11%	23.56%	★★★★☆☆

Click here to see the full list of 4658 stocks from our Undiscovered Gems With Strong Fundamentals screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Consun Pharmaceutical Group (SEHK:1681)

Simply Wall St Value Rating: ★★★★★★

Overview: Consun Pharmaceutical Group Limited focuses on the research, development, manufacturing, and sale of Chinese medicines and medical contrast medium products in China, with a market capitalization of HK$6.44 billion.

Operations: The company generates revenue primarily from the Consun Pharmaceutical Segment, contributing CN¥2.33 billion, and the Yulin Pharmaceutical Segment, adding CN¥410 million.

Consun Pharma, a nimble player in the pharmaceuticals sector, has been trading at nearly 60% below its estimated fair value, suggesting potential undervaluation. Over the past year, earnings grew by 13.9%, surpassing the industry average of 9.4%, indicating robust performance. The company's debt-to-equity ratio has improved significantly from 27.7% to 12.7% over five years, reflecting effective financial management and reduced leverage risks. Recent changes in company bylaws aim to align with regulatory requirements and streamline governance structures, potentially enhancing operational efficiency moving forward while maintaining high-quality earnings and positive free cash flow.

• Click to explore a detailed breakdown of our findings in Consun Pharmaceutical Group's health report.

• Review our historical performance report to gain insights into Consun Pharmaceutical Group's's past performance.

Fujian Raynen Technology (SHSE:603933)

Simply Wall St Value Rating: ★★★★★☆

Overview: Fujian Raynen Technology Co., Ltd. operates in the IC distribution sector both within China and globally, with a market capitalization of CN¥3.38 billion.

Operations: Raynen Technology's revenue primarily stems from its IC distribution business. The company has a market capitalization of CN¥3.38 billion.

Fujian Raynen Technology, a burgeoning player in the semiconductor sector, has shown impressive earnings growth of 53.7% over the past year, outstripping the industry's 12.1%. The company’s price-to-earnings ratio of 46x is notably below the industry average of 65.9x, suggesting potential value for investors. Despite an increase in its debt to equity ratio from 15.4% to 27.7% over five years, its interest payments are well-covered by EBIT at a multiple of 7.3x. Recent results revealed net income climbing to CN¥60.58 million from CN¥46.18 million year-on-year for nine months ending September 2024.

• Take a closer look at Fujian Raynen Technology's potential here in our health report.

• Assess Fujian Raynen Technology's past performance with our detailed historical performance reports.

Jiangsu Ankura Intelligent Power (SZSE:300617)

Simply Wall St Value Rating: ★★★★★★

Overview: Jiangsu Ankura Intelligent Power Co., Ltd. operates in the electric equipment industry and has a market capitalization of CN¥4.93 billion.

Operations: Ankura Intelligent Power generates revenue primarily from its electric equipment segment, amounting to CN¥948.17 million. The company has a market capitalization of CN¥4.93 billion.

Jiangsu Ankura Intelligent Power is carving out a niche with earnings growth of 5.7% over the past year, outpacing the Electrical industry’s 1.1%. Its price-to-earnings ratio stands attractively at 28x, below the CN market average of 34.9x, indicating potential value. Despite recent challenges with net income dipping to CNY 135.99 million from CNY 160.98 million last year, it maintains high-quality earnings and has reduced its debt-to-equity ratio from 12.4% to 11.8% over five years, suggesting prudent financial management amidst fluctuating sales figures around CNY 669 million this period compared to last year's CNY 679 million.

• Navigate through the intricacies of Jiangsu Ankura Intelligent Power with our comprehensive health report here.

• Gain insights into Jiangsu Ankura Intelligent Power's historical performance by reviewing our past performance report.

Taking Advantage

• Get an in-depth perspective on all 4658 Undiscovered Gems With Strong Fundamentals by using our screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com